Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway.

Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, Nabel GJ.

J Virol. 2005 Jan;79(1):547-53.

2.

Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ.

Nat Med. 2000 Aug;6(8):886-9.

PMID:
10932225
3.

Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level.

Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, Ottmann M, Khromykh A, Volchkov VE.

J Gen Virol. 2006 May;87(Pt 5):1247-57.

PMID:
16603527
4.

Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.

Francica JR, Matukonis MK, Bates P.

Virology. 2009 Jan 20;383(2):237-47. doi: 10.1016/j.virol.2008.10.029. Epub 2008 Nov 14.

5.

Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.

Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y.

Virology. 2000 Dec 5;278(1):20-6.

6.
7.

Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P.

J Virol. 2002 Mar;76(5):2518-28.

8.

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.

Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR.

Antiviral Res. 2003 Mar;58(1):47-56.

PMID:
12719006
9.

Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C.

J Virol. 2007 Feb;81(4):1821-37. Epub 2006 Dec 6.

10.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

11.

Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.

Marzi A, Wegele A, Pöhlmann S.

Virology. 2006 Sep 1;352(2):345-56. Epub 2006 Jun 13.

12.

Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.

Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, Dolnik O, Klenk HD.

Science. 2001 Mar 9;291(5510):1965-9. Epub 2001 Feb 1.

13.

Epitopes required for antibody-dependent enhancement of Ebola virus infection.

Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S347-56.

PMID:
17940970
14.

Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.

Usami K, Matsuno K, Igarashi M, Denda-Nagai K, Takada A, Irimura T.

Biochem Biophys Res Commun. 2011 Apr 1;407(1):74-8. doi: 10.1016/j.bbrc.2011.02.110. Epub 2011 Mar 6.

PMID:
21362405
15.

Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Gustin JK, Bai Y, Moses AV, Douglas JL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S181-90. doi: 10.1093/infdis/jiv125. Epub 2015 Mar 27.

16.
17.

The pathogenesis of Ebola hemorrhagic fever.

Takada A, Kawaoka Y.

Trends Microbiol. 2001 Oct;9(10):506-11. Review.

PMID:
11597453
18.

Immunopathology of highly virulent pathogens: insights from Ebola virus.

Zampieri CA, Sullivan NJ, Nabel GJ.

Nat Immunol. 2007 Nov;8(11):1159-64. Review.

PMID:
17952040
19.

Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein.

Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P.

PLoS Pathog. 2010 Sep 9;6(9):e1001098. doi: 10.1371/journal.ppat.1001098.

20.

Shedding of Ebola Virus Surface Glycoprotein Is a Mechanism of Self-regulation of Cellular Cytotoxicity and Has a Direct Effect on Virus Infectivity.

Dolnik O, Volchkova VA, Escudero-Perez B, Lawrence P, Klenk HD, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S322-8. doi: 10.1093/infdis/jiv268. Epub 2015 Jun 19.

PMID:
26092855

Supplemental Content

Support Center